期刊文献+

清热活血方联合阿维A胶囊治疗红皮病型银屑病 被引量:8

下载PDF
导出
摘要 目的探讨清热活血方联合阿维A胶囊治疗红皮病型银屑病的临床效果。方法将我院自2016年1月—2017年1月间收治的红皮病型银屑病患者82例作为研究对象,按照患者入院接受治疗的顺序分为研究组和对照组,每组各有患者41例,研究组患者给予清热活血方联合阿维A胶囊进行治疗,对照组患者单纯给予阿维A胶囊进行治疗,比较2组患者的治疗效果。结果经过治疗,研究组患者临床总有效率为97.56%,明显高于对照组80.49%,不良反应发生率为14.64%,明显低于对照组34.16%,差异有统计学意义(P<0.05);经过治疗2组患者银屑病皮损面积与严重程度指数(PASI)积分均明显降低,其中研究组患者降低程度明显优于对照组,差异有统计学意义(P<0.05)。结论红皮病型银屑病患者使用清热活血方联合阿维A胶囊治疗可获得较好的临床效果,不良反应少且患者依从性好,可在临床范围内推广使用。
出处 《中国中西医结合皮肤性病学杂志》 CAS 2018年第3期249-251,共3页 Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
  • 相关文献

参考文献6

二级参考文献34

  • 1Parisi R, Symmons D P M, Cn'iffiths C E M, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. Jour- nal of Investigative Dermatology, 2013, 133(2): 377-385.
  • 2Langley R G, Elewski B E, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials [J]. New England Journal of Medicine, 2014, 371(4): 326-338.
  • 3Papp K A, Langley R G, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose ranging study[J]. British Journal of Dermatology, 2013, 168(2): 412-421.
  • 4Armstrong A W, Harskamp C T, Armstrong E J. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis[J]. JAM& dermatology, 2013, 149(1): 84-91.
  • 5Armstrong A W, Harskamp C T, Armstrong E J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of obser- vational studies [J]. Journal of the American Academy of Dermatolo- gy, 2013, 68(4): 654-662.
  • 6Papp K A, C_niffiths C E M, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final re- suits fi'om 5 years of follow-up [J]. British Journal of Dermatology, 2013, 168(4): 844-854.
  • 7Martin D A, Towne J E, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings [J]. Journal of Investigative Dermatology, 2013, 133(1): 17-26.
  • 8Tzellos T, Kyrgidis A, Zouboulis C C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with an- ti-IL-12/23 biological agents for chronic plaque psoriasis: a meta- analysis of randomized controlled trials [J]. Journal of the European Academy of Dermatology and Venereology, 2013, 27(5): 622-627.
  • 9Yeuag H, Takeshita J, Meitta N N, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study [J]. JAMA dermatology, 2013, 149(10): 1173-1179.
  • 10Armstrong A W, Robertson A D, Wu J, et al. Undertreatment, treat- ment trends, and treatment di ssati sfacti on among patients with psori a- sis and psoriatic arthritis in the United States: findings from the Na- tional Psoriasis Foundati on surveys, 2003-2011 [J]. JAMA dermatology, 2013, 149(10): 1180-1185.

共引文献66

同被引文献81

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部